[
  {
    "ts": "2025-06-20T23:15:00+00:00",
    "headline": "Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions",
    "summary": "BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American",
    "url": "https://finance.yahoo.com/news/vertex-presents-positive-data-zimislecel-231500649.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "cb1ba60c-6472-397e-a672-8b85d711b92a",
      "content": {
        "id": "cb1ba60c-6472-397e-a672-8b85d711b92a",
        "contentType": "STORY",
        "title": "Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions",
        "description": "",
        "summary": "BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American",
        "pubDate": "2025-06-20T23:15:00Z",
        "displayTime": "2025-06-20T23:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/ae46fec8c01da3d7fc40c222a65e4c70",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bWUnBHclpeYowsSz.BdHgw--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ae46fec8c01da3d7fc40c222a65e4c70.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cx9r.xJyN8gFUW3BHb8zUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ae46fec8c01da3d7fc40c222a65e4c70.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-presents-positive-data-zimislecel-231500649.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-presents-positive-data-zimislecel-231500649.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-20T20:07:13+00:00",
    "headline": "Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic […]",
    "url": "https://finance.yahoo.com/news/vertex-vrtx-stock-pt-lowered-200713846.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8828a6ef-39d7-384d-b931-abdf4b8766c2",
      "content": {
        "id": "8828a6ef-39d7-384d-b931-abdf4b8766c2",
        "contentType": "STORY",
        "title": "Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic […]",
        "pubDate": "2025-06-20T20:07:13Z",
        "displayTime": "2025-06-20T20:07:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t1jBIhwBTFbFoSQ67ljlOA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1VBe9WLhRv44nJzNTC.Feg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-vrtx-stock-pt-lowered-200713846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-vrtx-stock-pt-lowered-200713846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]